Patents Examined by Addison D Ault
  • Anthropogenic insect-resistant gene and Cry1C toxin idiotype single-chain antibody encoded thereby and application thereof
    Patent number: 9745385
    Abstract: An anthropogenic insect-resistant gene having a nucleotide sequence represented by SEQ ID NO.1, and a Cry1C toxin idiotype single-chain antibody encoded by said anthropogenic insect-resistant gene and having an amino acid sequence represented by SEQ ID NO.2; the antibody is a ?-type and has insecticidal activity, and after expression by the prokaryotic system, the primary culture thereof has binding activity to Cnaphalocrocis medinalis midgut peritrophic membrane specific receptor BBMV; the ?-type Cry1C toxin idiotype single-chain antibody of the present invention is obtained without animal immunization, has a short preparation period and small amino acid sequence, and is suitable for large-scale in vitro production.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: August 29, 2017
    Assignee: JIANGSU ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Xianjin Liu, Chongxin Xu, Xiao Zhang, Yuan Liu, Yajing Xie, Cunzheng Zhang, Xiangyang Yu, Donglan Wang
  • Peptides and uses thereof
    Patent number: 9732129
    Abstract: Disclosed herein are zinc finger peptides having at least 4 zinc finger domains, such as 6, 11, 12 or 18 zinc finger domains. The zinc finger peptides may be fused to effector domains for modulating gene expression. Zinc finger peptides of the invention are useful for targeting trinucleotide-repeat sequences in mutant genes and may have applications in gene therapy. The zinc finger peptides may have nucleic acid recognition sequences according to SEQ ID NO: 101. Also disclosed are methods for constructing poly-zinc finger peptides having arrays of at least 8 zinc finger domains, along with zinc finger frameworks that may be useful for selecting zinc finger peptides from libraries.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: August 15, 2017
    Assignee: Fundacio Centre de Regulacio Genomica
    Inventors: Mark Isalan, Mireia Garriga-Canut
  • Cell lines
    Patent number: 9732367
    Abstract: There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: August 15, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventors: Kenneth H. Grabstein, Michael Van Brunt, Marcello Marelli, William Brady, Jeffrey C. Johnson
  • Prognostic molecular signature of sarcomas, and uses thereof
    Patent number: 9708666
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of soft tissue sarcoma cancer phenotypes and soft tissue sarcoma cancer-associated diseases. Also described herein are methods that can be used to identify modulators of soft tissue sarcoma cancer.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: July 18, 2017
    Assignees: Université Bordeaux Segalen, Institut Bergonié, Institut curie
    Inventors: Frédéric Chibon, Jean-Michel Coindre, Alain Aurias
  • Sample fixation and stabilisation
    Patent number: 9696247
    Abstract: It has surprisingly been discovered that it is possible to stabilize biomolecules such as RNA, DNA and proteins in biological samples such as cells, tissues, biopsies and blood using deep eutectic solvents (DES). It has also been discovered that DES mixtures can be used to fix and preserve cell morphology in biological samples such as tissue blocks, cancer biopsies and whole blood. This invention describes methods to stabilize and preserve biomolecules, whole cells, tissues, blood and biological samples using DES mixtures.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: July 4, 2017
    Assignee: RNASSIST LTD.
    Inventors: Andres Simon Goldsborough, Malcolm Robert Bates
  • Salivary biomarkers for lung cancer detection
    Patent number: 9689039
    Abstract: Presented herein are biomarkers related to lung cancer. The presently identified salivary biomarkers create the basis for a lung cancer detection bioassay with sensitivity and specificity. Means and methods for evaluating the data generated using multiple biomarkers in order to validate findings and further use of the multiplexed lung cancer assay in clinical, diagnostic and therapeutic uses is also included.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: June 27, 2017
    Assignee: The Regents of the University of California
    Inventors: David T. Wong, Lei Zhang, Hua Xiao, Hui Zhou
  • Method for using directing cells for specific stem/progenitor cell activation and differentiation
    Patent number: 9670460
    Abstract: A method is provided, including obtaining a population of antigen-presenting cells, enriching a population of stem/progenitor cells within a larger population of cells, activating the population of antigen-presenting cells and, following the activating, inducing at least one process selected from the group consisting of: differentiation, expansion, activation, secretion of a molecule, and expression of a marker, by exposing the enriched stem/progenitor cell population to the population of antigen-presenting cells. Other applications are also described.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: June 6, 2017
    Assignee: BIOGENCELL, LTD.
    Inventor: Yael Porat
  • Lentiviral vectors containing an MHC class I, MHC class II, or B2 microglobulin upstream promoter sequence
    Patent number: 9657311
    Abstract: The present invention relates to the insertion of an MHC class I, MHC Class II, or ?2 microglobulin upstream promoter sequence into a lentiviral vector to increase viral titers. The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: May 23, 2017
    Assignee: THERAVECTYS
    Inventors: Cecile Bauche, Emeline Sarry
  • Methods and compositions for treating cancer
    Patent number: 9650428
    Abstract: Described are compositions and methods relating to immune cells which express both a chimeric antigen receptor which binds to the IL13 receptor ?-2 (IL13R?2) and a O6-methylguanine DNA methyltransferase (MGMT) protein. Viral particles containing an IL13 chimeric antigen receptor (IL13CAR) or variant thereof and an MGMT protein or variant thereof are used to transfect immune cells such as T cells, imparting to the transfected cells both IL13R?2-targeting activity and resistance to the chemotherapeutic agent temozolomide (TMZ). The compositions and methods described are useful for cancer therapy such as the treatment of a high-grade malignant glioma.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: May 16, 2017
    Assignee: Roger Williams Hospital
    Inventors: Prakash Sampath, Sadhak Sengupta, Richard P. Junghans
  • Reprogramming of cellular adhesion
    Patent number: 9650407
    Abstract: Disclosed are membrane-anchored polynucleotides, and compositions comprising the membrane-anchored polynucleotides. Also disclosed are the processes for the synthesis of these compounds, compositions comprising such compounds, and the use of such compounds and compositions in research and therapeutic applications.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: May 16, 2017
    Assignee: The Regents of the University of California
    Inventors: Zev Jordan Gartner, Nicholas Scott Selden, Michael E. Todhunter, Samantha Isabel Liang, Robert Joseph Weber, Noel Youngho Jee, Jennifer S. Liu
  • Single wall nanotube constructs and uses thereof
    Patent number: 9629927
    Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: April 25, 2017
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
  • Salivary transcriptomic and proteomic biomarkers for breast cancer detection
    Patent number: 9624547
    Abstract: Presented herein are biomarkers related to breast cancer. The presently identified salivary biomarkers create the basis for a breast cancer detection bioassay with sensitivity and specificity. Means and methods for evaluating the data generated using multiple biomarkers in order to validate findings and further use of the multiplexed breast cancer assay in clinical, diagnostic and therapeutic uses is also included.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: April 18, 2017
    Assignee: The Regents of the University of California
    Inventors: David T. Wong, Lei Zhang, Hua Xiao, Hui Zhou
  • Peptide inhibitors of BACE1
    Patent number: 9624269
    Abstract: The invention provides peptide inhibitors of BACE1 that bind to the active site in a noncanonical fashion, and methods of use thereof.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: April 18, 2017
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Yingnan Zhang, Weiru Wang
  • Composition for synthesizing protein with reduced lipopolysaccharide contamination, method for producing protein using said composition
    Patent number: 9617533
    Abstract: According to the present invention, a composition possessing cell-free protein synthesis activity with reduced contaminating lipopolysaccharide, and a method for producing a protein using the same are provided. When ribosome display is performed using the composition and method for protein production of the present invention, the background that is caused by non-specific binding is reduced, so that a nucleic acid that encodes the desired polypeptide can be selected with high accuracy and high efficiency.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: April 11, 2017
    Assignees: GeneFrontier Corporation, The Univeristy of Tokyo
    Inventors: Takashi Kanamori, Yuki Hayami, Kanehisa Kojoh, Takuya Ueda, Kumiko Tsuihiji, Tomoe Fuse, Mikiko Nakamura, Shizue Kato
  • Functionalized fluorine containing phthalocyanine molecules
    Patent number: 9572898
    Abstract: Functionalized fluorine containing phthalocyanine molecules, methods of making, and methods of use in diagnostic applications and disease treatment are disclosed herein. In some embodiments, the fluorine containing phthalocyanine molecules are functionalized with a reactive functional group or at least one cancer-targeting ligand (CTL). The CTL can facilitate more efficient binding and/or internalization to a cancer cell than to a healthy cell. The CTL can inhibit expression of oncoprotein in some embodiments. The pthalocyanine moiety can be used in diagnostic applications, such as fluorescence labeling of a cancer cell, and/or treatment applications, such as catalyzing formation of a reactive oxygen species (ROS) which can contribute to cell death of a cancer cell.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: February 21, 2017
    Assignee: Seton Hall University
    Inventors: David Sabatino, Sergiu M. Gorun, Emily Borland, Hemantbhai Patel, Pradeepkumar Patel, Erik Nathaniel Carrión
  • Generation of neural stem cells from human trophoblast stem cells
    Patent number: 9574173
    Abstract: Provided herein are isolated neural stem cells. Also provided are methods for treatment of neurodegenerative diseases using suitable preparations comprising the isolated neural stem cells.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: February 21, 2017
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Ying Lee, Yuta Lee, Eing-Mei Tsai
  • Method for directional cloning
    Patent number: 9567593
    Abstract: Described herein are techniques for directional cloning an insert DNA segments into a target vector. The techniques mix the target vector, the insert DNA segment, a restriction enzyme, and a DNA ligase to generate a recombinant DNA molecule.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: February 14, 2017
    Assignee: Innovative Cellular Therapeutics CO., LTD.
    Inventor: Zhao Wu
  • Transcription unit and use thereof in expression vectors
    Patent number: 9551009
    Abstract: A transcription unit constituted by a polynucleotide including the hCMVie virus enhancer, the enhancer having the nucleotide sequence SEQ ID NO: 1, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 1 and essentially having transcription activation properties, and the promoter region of Cyclin-Dependent Kinase 9 (CDK9), the promoter region having the nucleotide sequence SEQ ID NO: 2, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 2 and essentially having a promoter activity.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: January 24, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Alexandre Fontayne, Francois Coutard
  • Light-inducible promoter and gene expression system containing same
    Patent number: 9540653
    Abstract: The present invention relates to a light-inducible promoter and a gene expression system containing the same, and provides: a light-inducible promoter comprising a nucleotide sequence represented by SEQ ID NO: 12; and a method for producing heterologous proteins using the same. Since the light-inducible promoter of the present invention induces the expression of a gene by the irradiation of light and regulates an expression amount of the gene according to an intensity of light, it is possible to conveniently regulate the expression of the gene without straining the growth or metabolic process of an organism. In addition, the present invention can be applied to various types of organisms, and thus has a wide range of application.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: January 10, 2017
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Eon Seon Jin, Jae Hyeok Lee, Seung Hye Park, Kwang Ryul Baek
  • Vector comprising multiple homologous nucleotide sequences
    Patent number: 9540660
    Abstract: The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: January 10, 2017
    Assignee: BAVARIAN NORDIC A/S
    Inventor: Robin Steigerwald